| Literature DB >> 31333463 |
Megan L Shelby1, Wei He1, Amanda T Dang2, Tonya L Kuhl2, Matthew A Coleman1,2.
Abstract
Membranes proteins make up more than 60% of current drug targets and account for approximately 30% or more of the cellular proteome. Access to this important class of proteins has been difficult due to their inherent insolubility and tendency to aggregate in aqueous solutions. Understanding membrane protein structure and function demands novel means of membrane protein production that preserve both their native conformational state as well as function. Over the last decade, cell-free expression systems have emerged as an important complement to cell-based expression of membrane proteins due to their simple and customizable experimental parameters. One approach to overcome the solubility and stability limitations of purified membrane proteins is to support them in stable, native-like states within nanolipoprotein particles (NLPs), aka nanodiscs. This has become common practice to facilitate biochemical and biophysical characterization of proteins of interest. NLP technology can be easily coupled with cell-free systems to achieve functional membrane protein production for this purpose. Our approach involves utilizing cell-free expression systems in the presence of NLPs or using co-translation techniques to perform one-pot expression and self-assembly of membrane protein/NLP complexes. We describe how cell-free reactions can be modified to render control over nanoparticle size and monodispersity in support of membrane protein production. These modifications have been exploited to facilitate co-expression of full-length functional membrane proteins such as G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). In particular, we summarize the state of the art in NLP-assisted cell-free coexpression of these important classes of membrane proteins as well as evaluate the advances in and prospects for this technology that will drive drug discovery against these targets. We conclude with a prospective on the use of NLPs to produce as well as deliver functional mammalian membrane-bound proteins for a range of applications.Entities:
Keywords: cell-free; co-translation; membrane proteins; nanodisc; nanolipoprotein particle
Year: 2019 PMID: 31333463 PMCID: PMC6616253 DOI: 10.3389/fphar.2019.00744
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1Schematic for cell-free production of self-assembled nanolipoprotein particles (NLPs). Constituents (DNA, lipids, and cell-free extracts) are combined in a single reaction vial. The cell-free lysates utilize T7-coupled transcription and translation to produce fully formed disc shaped nanoparticles as imaged with transmission electron microscopy (TEM) (inset). The white scale bars are 20 nm.
Figure 2Schematic of two approaches for cell-free production of membrane proteins solubilized in NLPs: (A) The addition of fully formed NLPs, DNA encoding the membrane protein of interest, and additional lipid to a cell-free extract results in NLP solubilized receptor (Katzen et al., 2008). (B) Co-translation uses the addition of only plasmids encoding the ApoA1 and membrane protein of interest and lipid to a cell-free extract resulting in NLP solubilized receptor (Cappuccio et al., 2008).
Examples of cell-free co-translated membrane proteins associated with nanolipoprotein particles (NLPs).
| Membrane protein | Protein molecular weight | NLP diameter (nm) | Measuring technique | Cell-free references |
|---|---|---|---|---|
| Yop B + Yop D | 42 + 33 kDa | 18.9 ± 4.9 | AFM |
|
| NK1R | 46 kDa | 10.3 ± 7.5 | FCS |
|
| β2AR | 47 kDa | 33.0 ± 3.0 | TEM |
|
| BR | 28 kDa | 7.8 ± 2.8 | FCS |
|
| MOMP | 40 kDa | 39.8 ± 4.2 | DLS |
|
| ERBB2 (HER2) | 138 kDa | 12.5 | SAXS |
|
| EGFR | 134 kDa | 30.1 | DLS |
|
Yop, Yersinia outer protein; NK1R, neurokinin1 receptor; β2AR, beta-2 adrenergic receptor; BR, bacteriorhodopsin; MOMP, chlamydia major outer membrane protein; AFM, atomic force microscopy; FCS, fluorescence correlation spectroscopy; TEM, transmission electron microscopy; DLS, dynamic light scattering; SAXS, small-angle X-ray scattering.
Figure 3Cell-free co-expression for production of G-protein-coupled receptor (GPCR)-NLP complexes. (A) Illustrated β2-adrenergic receptor (β2AR) embedded in an NLP via cell-free expression and self-assembly. (B) Atomic force microscopy (AFM) image of NLPs with inserted GPCRs to determine the insertion rate based on the increase in the diameter of the disc. The inset shows an AFM image. The scale bar is 50 nm. (C) A histogram showing ligand binding for cell-free produced dopamine receptor D1 (DRD1) and β2AR (ADRB2). Data is based on fluorescent filter binding. (D) Fluorescence correlation spectroscopy (FCS) analysis of ligand concentration dependent binding is illustrated for the NK1 GPCR. An increase in the ligand concentration shows increased binding based on the shift of the spectrum to the right.
Figure 4Cell-free co-expression for production of ERBB (erythroblastic oncogene B) tyrosine kinase complexes. (A) Illustrated ERBB2 receptor embedded in an NLP via cell-free expression and self-assembly. (B) Analysis of the co-expression of EGFR (epidermal growth factor receptor) and ERBB2 in the presence of the plasmid encoding an ApoA1 gene via 4–20% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Visualization was accomplished via the incorporation of a fluorescent bodipy lysine dye. (C) NLP associated ERBB2 is tyrosine phosphorylated. Cell-free expressions were set up with and without (−) ERBB2 plasmid. Samples were collected at 2 h, and 5 h, resolved by SDS-PAGE and western blotted with anti-phospho-tyrosine ERBB2 antibody pY1248 and anti-ERBB2 antibody Ab-3 after stripping. (D) NLP associated EGFR is phosphorylated, and the presence of EGF in the cell-free reaction increases the level of phosphorylation. EGFR-NLPs showed low level of phosphorylation during cell-free expression. Adding EGF, the natural ligand of EGFR, increased the phosphorylation. Cell-free mixtures were resolved by SDS-PAGE and western blotted with anti-phospho-tyrosine EGFR antibody pY1110 and anti-EGFR. Images were spliced lanes from the same Western blot.